$CAEH: The company expects to complete agreements with local distribution partners in five additional European countries.

CAEH -

http://calecopharmaeurope.com/

http://www.lamiridosin.eu/?page_id=15

"The launch of our first commercial product, LamiriDOSIN represents the first step in our strategy to bring initial revenue to the company from the development and sales of over-the-counter supplements and dermatologic products derived from the company's proprietary liver formulation, while continuing pre-clinical development of two additional 'liver health formula' derivatives; CPC.12115HP201 and CPC.12115HP202 as potential prescription drugs. CPC.12115HP201 and CPC.12115HP202 have

shown significant anti-viral activity in vitro

To date, Caleco's intellectual property covering the "Liver Health" formulations is comprised of patent applications in the United States, Europe and Canada and four European Drug Master File applications.